The EPA told the AHA’s Association for the Healthcare Environment that recent testing gives the agency reason to believe sBioMed’s Steriplex SD Part A and Steriplex SD Activator Part B products are “misbranded pesticides” and are not effective against C. diff, as advertised.
The order requires sBioMed to voluntarily recall the products from the market until the compliance issues can be resolved.
EPA officials also recommend hospitals and healthcare facilities that use these pesticides “find alternative EPA-registered products which control [C. diff].”
More articles on C. diff:
Abnormal vitals and blood tests linked to C. diff complications
C. diff is over diagnosed by popular molecular tests, study finds
Which 9 hospitals reported zero C. diff and MRSA infections?
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.